El interés en corto de Virpax Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Virpax Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Virpax Pharmaceuticals (NASDAQ:VRPX) Bolsa, Informe de interés en corto

Virpax Pharmaceuticals

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals Inc

WIIM

PRZO

PanZero Technologies shares are trading higher after the company announced it secured a new order for its advanced counter-drone system from global defense and intelligence OEM amid growing demand for C-UAS solutions.

Wells Fargo analyst Timur Braziler maintains East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) with a Overweight and raises the price target from $95 to $97.

News

Price Target

Analyst Ratings

EWBC

Wells Fargo Maintains Overweight on East West Bancorp, Raises Price Target to $97

Macro Notification

General

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Israeli Military Following Iran's Attack Says 'We Will Choose When To Prove Our Precise And Surprising Attack Capabilities'

Wells Fargo analyst Timur Braziler maintains First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) with a Equal-Weight and raises the price target from $20 to $22.

Wells Fargo Maintains Equal-Weight on First BanCorp, Raises Price Target to $22

Semiconductor chip stocks led by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) noted investor selloff since Friday after gaining from Micron Technology, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) upbeat quarterly print and U.S. Fed rate cut to boost demand.
Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Qualcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), Micron, Analog Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>), Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Marvell Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) are trading lower Tuesday. Semiconductor ETFs VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) are down over 3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41124391/qualcomm-partners-with-stmicroelectronics-to-boost-ai-powered-iot-connectivity" rel="noreferrer noopener">Qualcomm Partners With STMicroelectronics To Boost AI-Powered IoT Connectivity</a>
The street remains jittery over <a target="_blank" href="https://www.benzinga.com/news/24/10/41119735/nvidia-faces-new-competition-cerebras-files-for-ipo-huawei-pushes-ai-chips" rel="noreferrer noopener">artificial intelligence prospects</a> as analysts flagged Nvidia&#8217;s dependence on four customers, which are also developing in-house chips, and its delays in product releases.
Though China urges its companies to adopt domestic AI chipmakers, National Science and Technology Council (NSTC) Minister Wu Cheng-wen said China lags behind Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/government/24/10/41114632/taiwan-semiconductors-2-nm-breakthrough-puts-taiwan-a-decade-ahead-of-chinas-semiconductor-industry" target="_blank" rel="noreferrer noopener">advanced technology semiconductor manufacturing</a> by at least a decade. Taiwan Semiconductor is a crucial supplier for Nvidia and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
The U.S. Chips Act played a crucial role in helping America develop its semiconductor base by offering <a target="_blank" href="https://www.benzinga.com/government/24/09/41007184/taiwan-semi-secures-7-5b-boost-for-arizona-expansion-aims-for-advanced-chip-production-report" rel="noreferrer noopener">subsidies to chipmakers</a> to boost artificial intelligence chip production in the country.
The semiconductor sector could see another tailwind if the Biden administration inks a bill to fastrack the specific semiconductor manufacturing projects that receive subsidies through the Chips Act by diluting the federal environmental scrutinies.
The legislation would exempt qualifying chip projects from reviews under the National Environmental Policy Act, the New York Times <a href="https://www.nytimes.com/2024/10/01/us/politics/biden-semiconductor-environmental-review.html" target="_blank" rel="noreferrer noopener">reports</a>.
Struggling chipmaker Intel recently got a boost from <a href="https://www.benzinga.com/news/24/09/40897994/whats-going-on-with-intel-stock-on-tuesday" target="_blank" rel="noreferrer noopener">$3 billion in direct funding</a> under the Chips Act in addition to the $8.5 billion in grants and $11 billion in loans that the company previously won under the act.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41124123/micron-set-for-profit-surge-with-high-margin-products-and-ai-driven-market-expansio" target="_blank" rel="noreferrer noopener">Micron Set for Profit Surge with High-Margin Products and AI-Driven Market Expansion, Analyst Says</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Tech

Media

AAPL

AVGO

INTC

MRVL

NVDA

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Despite Nvidia Selloff, Biden's Law and Taiwan Semi's Advantage Offer Growth Potential

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock&#39;s price, do they really matter?
Let&#39;s take a look at what these Wall Street heavyweights have to say about Archrock Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aroc#NYSE">AROC</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Archrock Inc. currently has an average brokerage recommendation of 1.33, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by six brokerage firms. An ABR of 1.33 approximates between Strong Buy and Buy.
Of the six recommendations that derive the current ABR, four are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.7% and 33.3% of all recommendations.
<h2>Brokerage Recommendation Trends for AROC</h2>
<img alt="Broker Rating Breakdown Chart for AROC" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/AROC_10012024.png" style="width:100%" title="" /> 
The ABR suggests buying Archrock Inc., but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock&#39;s near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
<h2>Zacks Rank Should Not Be Confused With ABR</h2>
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company&#39;s changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
<h2>Is AROC a Good Investment?</h2>
In terms of earnings estimate revisions for Archrock Inc., the Zacks Consensus Estimate for the current year has increased 3.4% over the past month to $1.04.
Analysts&#39; growing optimism over the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Archrock Inc.
Therefore, the Buy-equivalent ABR for Archrock Inc. may serve as a useful guide for investors.
<a href="https://www.zacks.com/stock/news/2343974/wall-street-analysts-think-archrock-inc-aroc-is-a-good-investment-is-it?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2343974">To read this article on Zacks.com click here.</a>

Earnings

Mid Cap

Markets

Trading Ideas

AROC

Wall Street Analysts Think Archrock Inc. Is a Good Investment: Is It?

LBPH

Shares Of Longboard Pharmaceuticals See Volume; Hearing Traders Circulating Mentions Of Co. On M&A Blog

BCTX

BriaCell Therapeutics shares are trading lower after the company announced a $5.13 million offering of shares and warrants priced at $0.975 per unit.

Wells Fargo analyst Timur Braziler maintains First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) with a Underweight and lowers the price target from $22 to $20.

Wells Fargo Maintains Underweight on First Hawaiian, Lowers Price Target to $20

Wells Fargo analyst Timur Braziler maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Equal-Weight and raises the price target from $85 to $92.

Wells Fargo Maintains Equal-Weight on Western Alliance, Raises Price Target to $92

Interest rates determine the risk and reward perceptions of virtually all asset classes in the financial market. The benchmark for return is&mdash;and has always been&mdash;the United States ten-year treasury bond yield, so when bond yields are high, investors tend to avoid higher-risk assets like stocks, as the risk is not worth it compared to bond yields.
Now that the Federal Reserve (the Fed) has lowered interest rates by the most since 2007, investors may think that lower returns could be ahead, especially now that the S&amp;P 500 has priced in most&mdash;if not all&mdash;of the potential effects these interest rate cuts have on the economy. Understanding that new money will shift into different market areas is key. Still, it all begins with knowing what interest rates will do in the coming quarters.
Sectors that typically have higher debts on their balance sheets are poised to benefit from lower interest rates. Lower interest expenses on that debt would drive up net income and earnings per share (EPS). For this reason, investors can find higher returns in sectors like consumer discretionary and the real estate sector.
<h2>Top Consumer Discretionary Stocks Poised for Higher Growth Ahead</h2>
This is one sector that could benefit from a double tailwind as interest rates work their way through the economy. Still, not all consumer discretionary stocks are made equal. This is going to be the case, especially for those with a smaller market capitalization and higher debt.
<h3>Analysts Expect Abercrombie&#39;s EPS to Jump 14.5% by 2025</h3>
Fitting this list, investors can see stocks like Abercrombie &amp; Fitch Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anf#NYSE">ANF</a>), with its $7.3 billion market capitalization today, carrying over 73% debt to equity on its balance sheet. This makes the company a prime target for an EPS expansion name, as lower interest rates help both consumer trends and lower interest expenses.
Wall Street knows this is the case, as analysts at Jefferies Financial Group see up to $220 as a price target for the company, calling for a net upside of 53.3% from where the stock trades today. More than that, Wall Street analysts expect to see EPS of $2.86 for the end of 2025, a jump of 14.5% from today&#39;s EPS of $2.5 in Abercrombie &amp; Fitch.
This growth in EPS and the higher valuation are driven by both the company&#39;s small size and the potential earnings expansion that can come from lowering interest expenses to push EPS higher to a point where current forecasts might be on the conservative side.
<h3>Chewy&#39;s Debt and Size Make It a Prime Target for Future Gains</h3>
Another name that is worth mentioning for a potential buy in this trend is Chewy Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chwy#NYSE">CHWY</a>) as a part of the consumer discretionary space with a healthy mix of consumer staples in the way that pet owners will always have room in their budgets to take care of their pets&#39; needs.
Because the company is only $12.6 billion in size and carries over 100% in debt compared to equity, it makes for a nearly perfect buy target in the coming quarters. This is why analysts at Piper Sandler see a price target on the stock of up to $35 a share, calling for a net upside potential of 16.3% from where it trades today.
More than that, bearish traders decided to trim their views on Chewy stock, as the short interest has declined by 2% over the past month alone to show capitulation from the bearish side of the market and opening room for bulls to take their places instead.
Among these bulls were Truist Financial and B. Riley Wealth Advisors, who boosted their holdings in Chewy stock by 39.3% and 74% as of August 2024. This would bring their net investments up to $2.5 million and $565,000 today.
<h2>Real Estate Stocks Poised for Growth Ahead of the Market</h2>
<h3>Healthpeak&#39;s Dividend and Growth Potential Make It a Standout REIT</h3>
Real estate stocks fit this same category. Because they need to acquire property and boost rental income, stocks like&nbsp;Healthpeak Properties Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/doc#NYSE">DOC</a>) shine. This $15.9 billion real estate investment trust (REIT) operates in the healthcare sector, an underrated growth source in the U.S. economy.
Wall Street analysts know that lower interest rates can help this company acquire more property and boost its bottom-line earnings, so Evercore decided to raise its price target to $26 a share for Healthpeak Properties. To prove these targets right, the stock must rally by as much as 15% from where it trades today.
Wall Street&#39;s earnings per share (EPS) forecasts are set at $0.44 a share for the next 12 months, up from today&#39;s $0.21 a share for a net 109.5% growth rate. This comes on top of one of the main benefits of investing in REITs: the dividend payout.
Healthpeak Properties offers a $1.2 payout for an annualized dividend yield of up to 5.3% to beat inflation and cushion any volatility that lower rates might bring into the market.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/lower-rates-higher-returns-key-stocks-to-watch-now/">Lower Rates, Higher Returns: Key Stocks to Watch Now</a>&quot; first appeared on MarketBeat.

Large Cap

REIT

Dividends

Real Estate

CHWY

Lower Rates, Higher Returns: Key Stocks to Watch Now

Phoenix Motor Says Determined The "Proterra Financial Statements" Is Incorrect

Cryptocurrency markets are trading lower amid escalating tensions in the Middle East.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$61,888.86&nbsp;&nbsp;</td>
<td>&nbsp;-2.5%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,498.87&nbsp;&nbsp;</td>
<td>&nbsp;-3.5%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$147.33&nbsp;&nbsp;</td>
<td>&nbsp;-5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1074&nbsp;&nbsp;</td>
<td>&nbsp;-9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001633</td>
<td>-8.3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increased by around 99% and daily active addresses rose by 7.1%. Transactions greater than $100,000 are up from 5,655 to  9,193 in a single day. Exchanges netflows are down by 1,521.2%.</li>
<li>Coinglass data reports 159,405 traders were liquidated in the past 24 hours for $482.24 million, with crypto long liquidations of $361.8 million at the highest since Aug. 5. Bitcoin long liquidations of $90.7 million are at the highest level since Aug. 5.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41125099/ripple-receives-dubai-approval-for-blockchain-payment-services">Ripple Receives Dubai Approval For Blockchain Payment Services</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122002/playbux-ceo-envisions-web3-future-where-crypto-is-earned-via-gaming-shopping">Playbux CEO Envisions Web3 Future Where Crypto Is Earned Via Gaming, Shopping</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41120425/arthur-hayes-cites-money-printing-as-key-factor-for-bitcoin-becoming-the-best-performing-a">Arthur Hayes Cites &#8216;Money Printing&#8217; As Key Factor For Bitcoin Becoming The &#8216;Best Performing Asset&#8217; In History</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41111755/robinhood-markets-launches-crypto-transfers-in-europe-enabling-bitcoin-ethereum-and-solana">Robinhood Markets Launches Crypto Transfers In Europe, Enabling Bitcoin, Ethereum, And Solana Transactions With 1% Deposit Match For A Limited Time</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41114110/the-dollar-is-weakening-heres-why-that-could-be-good-for-bitcoin-10x-research">The Dollar Is Weakening—Here&#8217;s Why That Could Be Good For Bitcoin: 10x Research</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41109127/asias-microstrategy-metaplanet-grabs-107-additional-bitcoins-to-boost-portfolio-by-nearly-">&#8216;Asia&#8217;s MicroStrategy&#8217; Metaplanet Boosts Portfolio With Fresh Acquisition Of 107 Bitcoins Worth Nearly $7M</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Arweave (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">AR</a>)</td>
<td>&nbsp;$19.67</td>
<td>&nbsp;-15.7%</td>
</tr>
<tr>
<td>Gala (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">GALA</a>)</td>
<td>&nbsp;$0.02032&nbsp;&nbsp;</td>
<td>&nbsp;-13.9%</td>
</tr>
<tr>
<td>Notcoin (CRYPTO: NOT)</td>
<td>&nbsp;$0.007543</td>
<td>&nbsp;-13.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices retreating lower to $61,000, crypto trader Cold Blooded Shiller stated that even anything down into the green box represents opportunity for some of the best risk-reward long exposure to six-figure Bitcoin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Do not forget, in the midset of the red candles that even anything down into the green box represents opportunity for some of the best risk-reward long exposure to 6-figure <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a>. <a href="https://t.co/AcMwgbZrFp">https://t.co/AcMwgbZrFp</a> <a href="https://t.co/IKf4GwQGB1">pic.twitter.com/IKf4GwQGB1</a>
&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1841170691556597971?ref_src=twsrc%5Etfw">October 1, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1841159390428115314">detailed</a> that Bitcoin has made a higher low and a higher high. He suggests the trend may have shifted from bearish to bullish.
Crypto trader Jelle compared the current Bitcoin price movement to its historical trends. He predicts new legs to start in October, "breaking out in the 2nd or 3rd week of the month."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In the past bull-years, <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> has taken the summer to recharge, preparing for the next leg higher. All of those new legs higher started in October &#8211; breaking out in the 2nd or 3rd week of the month. I don&#39;t think this year is different. Final shakeout before new highs. <a href="https://t.co/CXEHhebEMU">pic.twitter.com/CXEHhebEMU</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1841153285580878310?ref_src=twsrc%5Etfw">October 1, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another crypto trader, IncomeSharks, <a href="https://x.com/IncomeSharks/status/1841173131572232524">believes</a> that if Bitcoin is able to re-test, "we continue back up."
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41119368/what-does-technical-analysis-say-about-bitcoin">What Does Technical Analysis Say About Bitcoin?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$GALA

$SHIB

$SOL

Bitcoin, Ethereum, Dogecoin Begin 'Uptober' Deep In The Red, But Traders See This As The 'Final Shakeout'

Ethereum Classic (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/etc/usd">ETC</a>) is trading lower by 6.2% to $18.50 during Tuesday&#8217;s session amid overall market weakness. Iran earlier launched a <a href="https://www.benzinga.com/news/global/24/10/41126038/iran-attacks-israel-with-missiles-middle-east-tensions-escalates-s-p-500-stocks-bitcoin-fall-as-oil">missile strike</a> against Israel, following the assassination of Hezbollah leader Hassan Nasrallah.
The attack, which saw between 100 to 200 missiles fired, marked a new escalation in regional tensions, with fears mounting over a broader conflict. In response, the United States bolstered its military presence, signaling the potential for further retaliatory action.
The sudden rise in conflict and uncertainty has rattled global markets, driving up safe-haven assets like gold and oil, while riskier assets such as cryptocurrencies took a hit.
Read Also: <a href="https://www.benzinga.com/news/24/10/41126631/hurricane-helene-devastation-the-latest-on-damage-companies-affected">Hurricane Helene Devastation: The Latest On Damage, Companies Affected</a>
What To Know: Cryptocurrencies, including Ethereum Classic, often see heightened volatility during periods of geopolitical unrest. As a smaller and more niche asset compared to Bitcoin or Ethereum, Ethereum Classic tends to be more vulnerable to sharp price movements during uncertain times. 
The growing conflict between Iran and Israel, with the involvement of the United States, has triggered widespread market anxiety. Investors, concerned about the potential impact on the global economy and energy markets, are fleeing riskier assets like ETC in favor of traditional safe-havens.
What Else: While Ethereum Classic has its own dedicated user base and unique blockchain infrastructure, it remains highly correlated with the broader cryptocurrency market. As political instability drives fear across global markets, investors are pulling back from cryptocurrencies as a whole.
Additionally, regulatory uncertainty around cryptocurrencies in regions like the U.S. and Europe, combined with the instability in the Middle East, is causing further trepidation among investors. 
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41122944/east-coast-dockworkers-strike-how-labor-dispute-impacts-economy-logistics-companies">East Coast Dockworkers Strike: How Labor Dispute Impacts Economy, Logistics Companies</a>

$ETC

Why Ethereum Classic Is Falling

The United Kingdom could generate between $4.38 billion and $12.6 billion annually in tax revenue by legalizing and regulating cannabis for adult use, according to a new <a href="https://clearmembers-uk.org/wp-content/uploads/2024/09/CLEAR-plan-V3.pdf">report</a> by CLEAR, a cannabis reform advocacy group. The paper lays out a detailed framework for the UK&#8217;s potential cannabis industry, from cultivation to retail.
The report proposes establishing a cannabis inspectorate to oversee commercial cultivation, importation, distribution and taxation. The aim is to create a regulated market similar to <a href="https://www.benzinga.com/general/biotech/24/05/39076458/canadian-cannabis-market-trends-sales-increase-as-youth-impact-study-unfolds">Canada&#8217;s</a>, where after six years, over 70% of all cannabis sales occur through legal channels.
<h3 class="wp-block-heading">Cannabis Market Could Stabilize Illicit Trade</h3>
The piece highlights how <a href="https://www.benzinga.com/topic/cannabis-regulation">cannabis regulation</a> could help control the UK's illicit cannabis market, currently valued between £2.9 billion ($3.84B) and £8.8 billion ($11.67B) per year. By implementing a £1-per-gram cannabis tax ($1.33 dollars), the Treasury could gain substantial revenue while avoiding the pitfalls of over-taxation seen in states like <a href="https://www.benzinga.com/markets/cannabis/24/04/38387994/california-cannabis-industry-is-drowning-in-debt-732m-owed-in-taxes-72-by-companies-already-clos">California</a>, where the illicit market <a href="https://www.benzinga.com/markets/cannabis/24/06/39188435/californias-cartel-cannabis-flourishes-in-national-parks-weed-grown-on-public-lands-accounts-for">continues to thrive</a> despite legalization.
"There isn't really any coherent argument against regulating cannabis," Peter Reynolds, president of CLEAR <a href="https://www.leafie.co.uk/news/cannabis-legalisation-worth-9-billion-uk/">told</a> Leafie. "It will reduce crime, violence, street dealing, underage use and help to prevent children from being dragged into gangs." Reynolds expressed frustration over the lack of political will to address cannabis reform. "The real problem is that our politicians don't have the courage even to discuss it."
<h3 class="wp-block-heading">New Approach To Cannabis Cultivation</h3>
CLEAR's proposal outlines a permissive yet structured approach to home cultivation, suggesting adults should be allowed to grow up to three indoor cannabis plants, plus three more under natural light, or a total of six plants outdoors. The plan also proposes a separate space for cuttings and seedlings. Unlike other countries with more restrictive cultivation laws, the UK could lead in allowing more personal freedom for home growers.
Reynolds further emphasized the economic benefits of legalizing cannabis. "Our proposals are business-friendly," he said. "Get this right, and we can create thousands of new jobs, fight crime and protect children. When will our politicians wake up?"
<h3 class="wp-block-heading">Potential Social And Health Benefits</h3>
Beyond economic gains, regulation could lead to significant public health benefits. The report cites studies showing that <a href="https://www.benzinga.com/markets/cannabis/24/05/38952528/cannabis-legalization-22m-us-teenagers-are-less-interested-in-weed-in-states-where-its-legal-go-">cannabis regulation reduces teen use</a>, lowers alcohol and cigarette consumption and decreases opioid-related deaths. An estimated 1.5 to 2.7 million people in the UK use cannabis monthly, with about 10 million having used it in the past year. Regulation would provide a safer environment for this significant portion of the population. However, the report also cautions against over-taxation.
The California model is often cited as an example of how high tax rates can drive consumers back to illicit markets. Instead, CLEAR points to <a href="https://www.benzinga.com/topic/canada-cannabis">Canada</a> as a model for success, where government regulation has been more effective in curbing illegal sales and maintaining price stability.
Cover image made with AI

Cannabis

Retail Sales

UK Could Net Up To $12.6B Annually From Cannabis Legalization

Wells Fargo analyst Matthew Akers maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Underweight and lowers the price target from $119 to $110.

Wells Fargo Maintains Underweight on Boeing, Lowers Price Target to $110

Pentagon Says U.S. Fully Supports Israel's Right To Defend Itself After Iran's "Significant" Attack

Wells Fargo analyst Matthew Akers maintains Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) with a Overweight and raises the price target from $165 to $185.

Wells Fargo Maintains Overweight on Booz Allen Hamilton, Raises Price Target to $185

U.S. State Department Says Israel Has The Right To Defend Itself, But We Will Coordinate With Them On What Any Response Looks Like

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let&#39;s see what these Wall Street heavyweights think about Arista Networks (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anet#NYSE">ANET</a>).
Arista Networks currently has an average brokerage recommendation of 1.67, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 23 brokerage firms. An ABR of 1.67 approximates between Strong Buy and Buy.
Of the 23 recommendations that derive the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 65.2% and 8.7% of all recommendations.
<h2>Brokerage Recommendation Trends for ANET</h2>
<img alt="Broker Rating Breakdown Chart for ANET" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ANET_10012024.png" style="width:100%" title="" /> 
While the ABR calls for buying Arista Networks, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>ABR Should Not Be Confused With Zacks Rank</h2>
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
<h2>Is ANET a Good Investment?</h2>
In terms of earnings estimate revisions for Arista Networks, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $8.24.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Arista Networks.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Arista Networks.
<a href="https://www.zacks.com/stock/news/2343971/wall-street-analysts-think-arista-networks-anet-is-a-good-investment-is-it?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2343971">To read this article on Zacks.com click here.</a>

ANET

Wall Street Analysts Think Arista Networks Is a Good Investment: Is It?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Wednesday morning!



Moving stocks are merger plans, a new contract, a CEO departure and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Gabelli Multi-Media Trust Inc. (The) Rights (expiring July 22, 2024) Rights (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGTR#NYSE">GGTR</a>) stock is rocketing 110% as the <a href="https://www.nasdaq.com/press-release/gabelli-multimedia-trust-alerts-common-stock-shareholders-rights-offering-expiration">rights offering expiration date closes in</a>.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are soaring more than 79% on an <a href="https://www.nasdaq.com/press-release/aditxt-and-evofem-amend-and-restate-merger-agreement-targeting-september-30-closing">amended merger agreement</a>.</li>



<li>Shimmick (NASDAQ:<a href="https://investorplace.com/stock-quotes/shim-stock-quote/">SHIM</a>) stock is surging over 56% on a <a href="https://www.marketwatch.com/story/shimmick-shares-surge-on-27-6-million-california-contract-121fe14b?mod=investing">$27.6 million contract</a>.</li>



<li>Aura Fat Projects (NASDAQ:<a href="https://investorplace.com/stock-quotes/afar-stock-quote/">AFAR</a>) shares are gaining more than 33% without any clear news this morning.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is increasing over 22% with heavy pre-market trading.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rising more than 18% with strong pre-market trading.</li>



<li>GitLab (NASDAQ:<a href="https://investorplace.com/stock-quotes/gtlb-stock-quote/">GTLB</a>) stock is climbing close to 16% higher on <a href="https://finance.yahoo.com/news/exclusive-google-backed-software-developer-060252892.html">reports it&rsquo;s considering a sale</a>.</li>



<li>Bloom Energy (NYSE:<a href="https://investorplace.com/stock-quotes/be-stock-quote/">BE</a>) shares are heading over 14% higher on a new <a href="https://finance.yahoo.com/news/bloom-energy-coreweave-partner-revolutionize-200500337.html">artificial intelligence (AI) data center partnership</a>.</li>



<li>Immersion (NASDAQ:<a href="https://investorplace.com/stock-quotes/immr-stock-quote/">IMMR</a>) stock is jumping nearly 12% this morning.</li>



<li>Eledon Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/eldn-stock-quote/">ELDN</a>) shares are up more than 11% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Five Below (NASDAQ:<a href="https://investorplace.com/stock-quotes/five-stock-quote/">FIVE</a>) stock is diving over 16% with the <a href="https://www.nasdaq.com/press-release/five-below-inc-announces-ceo-transition-2024-07-16">departure of its CEO</a>.</li>



<li>New Horizon Aircraft (NASDAQ:<a href="https://investorplace.com/stock-quotes/hovr-stock-quote/">HOVR</a>) shares are tumbling more than 13% after <a href="https://www.nasdaq.com/press-release/horizon-aircraft-attend-farnborough-international-airshow-2024-2024-07-15">rallying yesterday on airshow plans</a>.</li>



<li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is taking an over 12% beating on Wednesday morning.</li>



<li>Greenpro Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) shares are sliding more than 12% after <a href="https://www.accesswire.com/888710/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-with-bank-islam-trust-company-labuan-ltd">jumping yesterday on strategic alliance news</a>.</li>



<li>Cineverse (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnvs-stock-quote/">CNVS</a>) stock is dropping over 10% on Wednesday.</li>



<li>Virpax Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrpx-stock-quote/">VRPX</a>) shares are decreasing almost 10% after rallying yesterday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is falling more than 9% after a similar rally yesterday.</li>



<li>Eightco (NASDAQ:<a href="https://investorplace.com/stock-quotes/octo-stock-quote/">OCTO</a>) shares are slipping over 9% <a href="https://www.stocktitan.net/news/OCTO/eightco-provides-shareholder-8okhfyrirfyb.html">following a shareholder update</a>.</li>



<li>Xeris Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/xers-stock-quote/">XERS</a>) stock is dipping more than 9% on Wednesday morning.</li>



<li>Logistic Properties of The Americas (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lpa-stock-quote/">LPA</a>) shares close out our pre-market stock movers down 9% after a recent rally.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Personalis Inc., SunPower, and Virpax Pharmaceuticals are the 3 Penny Stocks to watch on July 23, based on&nbsp;TipRanks' Penny Stock Screener tool...

3 Penny Stocks to Watch Now, 7/23/24

Virpax regains compliance with Nasdaq minimum bid price

Virpax Pharmaceuticals files to sell common stock, warrants

The latest announcement is out from Virpax Pharmaceuticals (VRPX). Virpax Pharmaceuticals, Inc. has been given until September 30, 2024, to meet Na...

Virpax Pharmaceuticals Navigates Stock, Governance, and Compliance Challenges

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Virpax Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrpx-stock-quote/">VRPX</a>) just reported results for the second quarter of 2024.<ul><li>Virpax Pharmaceuticals reported earnings per share of -$1.75.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vrpx-stock-earnings-virpax-pharmaceuticals-for-q2-of-2024/">VRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q2 2024

Virpax Pharmaceuticals GAAP EPS of -$1.75

Virpax Pharmaceuticals (VRPX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Virpax Pharmaceuticals' Promising Outlook: Buy Rating Justified by Strategic Financial Management and Innovative Pain Management Pipeline

The latest announcement is out from Virpax Pharmaceuticals ( ($VRPX) ). Virpax Pharmaceuticals, Inc. has filed a Form 8-K report with the SEC to an...

Virpax Pharmaceuticals Announces Key Management Changes

Virpax Pharmaceuticals ( ($VRPX) ) has shared an announcement. Virpax Pharmaceuticals, Inc. has experienced significant changes, including the resi...

Virpax Pharmaceuticals Overhauls Leadership and Auditor Amid Concerns

ADTX

AFAR

APVO

CNVS

ELDN

FIVE

GGTR

GRNQ

GTLB

HOVR

IMMR

MLGO

OCTO

PSNL

SHIM

SOAR

SPWR

VRPX

XERS

Press Releases

Virpax Pharmaceuticals Reports 2023 Year-End Results

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™

Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

Virpax Announces Pricing of $2.25 Million Public Offering

Virpax® Pharmaceuticals to Present at 2024 BIO International Convention

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™

Virpax Regains Compliance with Nasdaq Minimum Bid Price

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

Comments

Virpax Pharmaceuticals

Interés en corto

Virpax Pharmaceuticals (NASDAQ:VRPX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL